Literature DB >> 19744401

Treatment of sleep dysfunction and psychiatric disorders.

Philip M Becker1, Muhammad Sattar.   

Abstract

Patients with neurologic disorders commonly experience sleep dysfunction and psychiatric disorders. The most common sleep dysfunction is insomnia, which is a primary symptom in 30% to 90% of psychiatric disorders. Insomnia and fatigue are prominent symptoms of anxiety disorders and major depression that may occur in patients who are treated but have residual sleep dysfunction. Anxiety and depressive disorders account for 40% to 50% of all cases of chronic insomnia. It is also recognized that primary insomnia and other primary sleep disorders produce symptoms that are similar to those reported by patients with psychiatric disorders. A clinician must judge whether sleep deprivation causes mood disturbance or whether depressive or anxiety disorder represents the primary reason for sleep dysfunction. When insomnia is comorbid with mild to moderate depression, therapy should begin with bedtime dosing of sedating antidepressants such as mirtazapine, nefazodone, or tricyclic antidepressants, which are preferred because of their sedative effects. Often side effects limit their usefulness. Intervention for chronic insomnia is similar in nonpsychiatric and psychiatric patients. Behavioral therapies, particularly multicomponent cognitive-behavioral therapy, and lifestyle changes show significant long-term efficacy as treatments for chronic insomnia. The most studied pharmacologic agents to treat insomnia are sedative hypnotic agents, particularly those that are active through the benzodiazepine receptor-GABA (gamma-aminobutyric acid) complex, such as benzodiazepines, eszopiclone, zaleplon, and zolpidem. Melatonin and the melatonin-receptor agonist ramelteon have not had adequate study in psychiatric patients to define their use, but small studies suggest benefit. Prescription of adjunctive trazodone (50-150 mg) is a common clinical practice to treat comorbid insomnia during antidepressant therapy, but published data are surprisingly limited, considering its frequent use. Although there has been insufficient research on the use of atypical antipsychotic agents in severe insomnia, psychiatrists use quetiapine, olanzapine, or others to lessen agitation that disrupts sleep. When insomnia or hypersomnia continue even as mood, anxiety, or thought disorders improve with standard therapy, the physician should consider the potential presence of underlying sleep disorders.

Entities:  

Year:  2009        PMID: 19744401     DOI: 10.1007/s11940-009-0039-z

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  43 in total

1.  Residual symptoms in depressed patients who respond acutely to fluoxetine.

Authors:  A A Nierenberg; B R Keefe; V C Leslie; J E Alpert; J A Pava; J J Worthington; J F Rosenbaum; M Fava
Journal:  J Clin Psychiatry       Date:  1999-04       Impact factor: 4.384

2.  A placebo-controlled test of cognitive-behavioral therapy for comorbid insomnia in older adults.

Authors:  Bruce Rybarczyk; Edward Stepanski; Louis Fogg; Martita Lopez; Paulette Barry; Andrew Davis
Journal:  J Consult Clin Psychol       Date:  2005-12

3.  Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults.

Authors:  N Breslau; T Roth; L Rosenthal; P Andreski
Journal:  Biol Psychiatry       Date:  1996-03-15       Impact factor: 13.382

Review 4.  Insomnia.

Authors:  Michael J Sateia; Peter D Nowell
Journal:  Lancet       Date:  2004 Nov 27-Dec 3       Impact factor: 79.321

5.  Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse.

Authors:  Charles M Morin; Lynda Bélanger; Célyne Bastien; Annie Vallières
Journal:  Behav Res Ther       Date:  2005-01

6.  Suicidality and sleep disturbances.

Authors:  Rebecca A Bernert; Thomas E Joiner; Kelly C Cukrowicz; Norman B Schmidt; Barry Krakow
Journal:  Sleep       Date:  2005-09       Impact factor: 5.849

Review 7.  Treatment of primary insomnia.

Authors:  Erika N Ringdahl; Susan L Pereira; John E Delzell
Journal:  J Am Board Fam Pract       Date:  2004 May-Jun

8.  Effects of a brief behavioral treatment for late-life insomnia: preliminary findings.

Authors:  Anne Germain; Douglas E Moul; Peter L Franzen; Jean M Miewald; Charles F Reynolds; Timothy H Monk; Daniel J Buysse
Journal:  J Clin Sleep Med       Date:  2006-10-15       Impact factor: 4.062

Review 9.  Treatment of insomnia associated with clinical depression.

Authors:  Ripu D Jindal; Michael E Thase
Journal:  Sleep Med Rev       Date:  2004-02       Impact factor: 11.609

10.  Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Jonathan W Stewart; Andrew A Nierenberg; Michael E Thase; Louise Ritz; Melanie M Biggs; Diane Warden; James F Luther; Kathy Shores-Wilson; George Niederehe; Maurizio Fava
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

View more
  8 in total

Review 1.  Defining and measuring functional recovery from depression.

Authors:  Tracy L Greer; Benji T Kurian; Madhukar H Trivedi
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

2.  Beyond fatigue: Assessing variables associated with sleep problems and use of sleep medications in multiple sclerosis.

Authors:  Alyssa M Bamer; Kurt L Johnson; Dagmar A Amtmann; George H Kraft
Journal:  Clin Epidemiol       Date:  2010-05-01       Impact factor: 4.790

3.  Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.

Authors:  Junshui Ma; Vladimir Svetnik; Ellen Snyder; Christopher Lines; Thomas Roth; W Joseph Herring
Journal:  Sleep       Date:  2014-10-01       Impact factor: 5.849

4.  Antidepressant use, depressive symptoms, and incident frailty in women aged 65 and older from the Women's Health Initiative Observational Study.

Authors:  Susan L Lakey; Andrea Z LaCroix; Shelly L Gray; Soo Borson; Carla D Williams; Darren Calhoun; Joseph S Goveas; Jordan W Smoller; Judith K Ockene; Kamal H Masaki; Mace Coday; Milagros C Rosal; Nancy F Woods
Journal:  J Am Geriatr Soc       Date:  2012-05-09       Impact factor: 5.562

5.  Health behaviors predict higher interleukin-6 levels among patients newly diagnosed with head and neck squamous cell carcinoma.

Authors:  Sonia A Duffy; Theodoros Teknos; Jeremy M G Taylor; Karen E Fowler; Mozaffarul Islam; Gregory T Wolf; Scott McLean; Tamer A Ghanem; Jeffrey E Terrell
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-01-08       Impact factor: 4.254

6.  Mapping of the Insomnia Severity Index and other sleep measures to EuroQol EQ-5D health state utilities.

Authors:  Ning Yan Gu; Marc F Botteman; Xiang Ji; Christopher F Bell; John A Carter; Ben van Hout
Journal:  Health Qual Life Outcomes       Date:  2011-12-30       Impact factor: 3.186

Review 7.  Update of sleep alterations in depression.

Authors:  Andrés Barrera Medina; DeboraYoaly Arana Lechuga; Oscar Sánchez Escandón; Javier Velázquez Moctezuma
Journal:  Sleep Sci       Date:  2014-09-27

Review 8.  Major depressive disorder: mechanism-based prescribing for personalized medicine.

Authors:  Philip F Saltiel; Daniel I Silvershein
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-31       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.